CN-680000-ME216-A5.pdf

AHCA CONTRACT NO. MED216

AMENDMENT NO. 5

AHCA Contract No. MED216, Amendment No. 5, Page 1 of 7

THIS CONTRACT, entered into between the STATE OF FLORIDA, AGENCY FOR HEALTH CARE ADMINISTRATION, hereinafter referred to as the "Agency," and FLORIDA MEDICAL SCHOOLS QUALITY NETWORK, INC., hereinafter referred to as the "Vendor," is hereby amended.

WHEREAS, the Contract expiration date is June 30, 2024; and

WHEREAS, the Agency is unable to provide the Vendor with the required data to complete the Biennial Sickle Cell Disease Study Report prior to the expiration of this Contract; and

WHEREAS, the Agency is extending this Contract for an additional six (6) months to allow the Vendor additional time to complete all requirements of the legislatively required Biennial Sickle Disease Study Report; and

WHEREAS, the Agency has identified formatting errors within Attachment I, Scope of Services, which started with changes made in Amendment 2, that need to be corrected.

NOW THEREFORE, the Agency and Vendor hereby agree to amend this Contract as follows:

1. In accordance with Section 287.057(13), Florida Statues, which provides for an extension of this Contract, the extended term shall begin July 1, 2024, for a period of six (6) months.

Therefore, Standard Contract, Section I., THE VENDOR HEREBY AGREES, Sub- Section W., Item 5., is hereby amended to now read as follows:

This Contract shall begin on July 26, 2021, and end on December 31, 2024.

2. Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1., Projects to be Completed by the Vendor, is hereby deleted in its entirely and is replaced as follows:

1. Projects to be Completed by the Vendor

a. Project 1: Study on the Use of Donor Human Milk (Completed)

The Vendor shall provide a timeline that provides a description of the activities and due dates that shall be completed for the Study on the Use of Donor Human Milk as a supplement to newborn care for infants born prematurely and hospitalized within the newborn intensive care unit (NICU) as described in the 2021 General Appropriations Act, Specific Appropriation 188. The timeline must, at a minimum, include due dates in which the below listed activities will be completed and submitted to the Agency:

i. A list of donor human milk banks and companies supplying donor-derived human milk to infants in Florida;

ii. Data showing the use by Florida hospitals of donor human milk made available via donor human milk banks and the related health outcomes and achieved cost-savings for both Medicaid and commercial payors regarding newborn care within a NICU;

DocuSign Envelope ID: DD7321A2-D5CB-4AD8-B034-D06BEE39C3E1DocuSign Envelope ID: 997AE366-BC46-4F1F-A3C1-D98CC8DA57D5

AHCA Contract No. MED216, Amendment No. 5, Page 2 of 7

iii. An itemized list and description of the safety considerations in utilizing human milk for newborns in the NICU and the adulterants and contaminants that can be transmitted via human milk.

iv. Recommendations of best practices which must address, at a minimum: the operation of a donor human milk tissue bank that facilitates the donation, processing and distribution of donor human milk tissue and donor human milk tissue derivatives; procedures for donation and distribution of donor human milk tissue and donor human milk tissue derivatives; and testing of donor human milk tissue and donor human milk tissue derivatives before donation, processing, and distribution to ensure the absence of adulterants and other contaminants as determined by the Agency.

b. Project 2: Sickle Cell Disease Study (Completed)

The purpose of this project is to conduct a study and produce a report on sickle cell disease as described in the 2022 General Appropriations Act, Specific Appropriation 189. The Agency shall submit the report to the Governor, the President of the Senate, the Speaker of the House of Representatives, Florida Department of Health Office of Minority Health and Health Equity and Rare Disease Advisory Council by February 1, 2023. The Vendor shall conduct the following activities, at a minimum, in meeting the requirements of this Contract:

i. Identify the total population of Medicaid enrollees with a diagnosis of sickle cell disease.

ii. Identify the total population of Medicaid enrollees who have experienced two (2) or more emergency room visits or two (2) or more inpatient admissions in the most recent Twelve (12) month period in which complete data is available as approved by the Agency.

iii. For both populations, provide the following detailed information:

1) Age and population demographics;

2) Health care utilization patterns

3) Expenditures for all pharmaceutical and medical services provided.

4) Number of clinical treatment programs available that are contracted with managed care plans for the care of Florida Medicaid enrollees that are specifically designed or certified to provide health care coordination and health care access for individuals with SCD.

DocuSign Envelope ID: DD7321A2-D5CB-4AD8-B034-D06BEE39C3E1DocuSign Envelope ID: 997AE366-BC46-4F1F-A3C1-D98CC8DA57D5

AHCA Contract No. MED216, Amendment No. 5, Page 3 of 7

iv. Consult with a dedicated sickle cell disease medical treatment and research center which maintains a sickle cell patient database and tracks sickle cell disease outcome measures.

v. Identify enrollees within the general sickle cell patient population who have experienced two or more emergency room visits or two or more hospital inpatient admissions in Twelve (12) month period.

For both of those populations, the Vendor shall provide detailed information including:

1) Age and population demographics.

2) Health care utilization patterns.

3) Expenditures for all pharmaceutical and medical services provided.

contracted with managed care plans for the care of Medicaid enrollees that are specifically designed or certified to provide health care coordination and health care access for individuals with sickle cell disease.

vi. Summarize evidence and best practice for sickle cell disease screening, diagnosis, treatment, and transition from the pediatric care setting to adult care setting.

vii. Criteria for Florida Centers of Excellence for Sickle Cell Disease

1) The Vendor shall review at least five (5) existing Centers of

Excellence (“Centers”) and identify any best practices that may support quality of health outcomes and health care value for Florida Medicaid recipients with sickle cell disease

(“SCD”).

2) The Vendor shall determine criteria for the creation of

Florida Centers of Excellence for Sickle Cell Disease with the purpose of increasing quality of health outcomes and health care value for Florida Medicaid recipients with SCD.

3) The Vendor shall produce a report containing a summary of input from the SCD work group members on criteria for the potential creation of Florida Centers of Excellence for Sickle Cell Disease.

4) The FMSQN workgroup may use the report and findings to share with our Colleges of Medicine leaders and State leadership as applicable and as approved by the Agency.

DocuSign Envelope ID: DD7321A2-D5CB-4AD8-B034-D06BEE39C3E1DocuSign Envelope ID: 997AE366-BC46-4F1F-A3C1-D98CC8DA57D5

AHCA Contract No. MED216, Amendment No. 5, Page 4 of 7

viii. Provider Education for Treating Patients with Sickle Cell Disease

1) The Vendor shall assess existing Florida provider education courses and shall propose topics for other modules based on identified gaps in existing provider education courses.

2) Upon Agency approval of proposed topics, The Vendor shall create modules that address gaps and expand on existing provider education courses.

ix. Preferred Drug List for Treating Patients with Sickle Cell Disease

1) The Vendor shall obtain and evaluate the current Medicaid fee-for-service preferred drug list (PDL), as well as non-covered drugs, for medications that are proven to benefit patients with SCD for efficacy, including indications for treatment, variety of agents, dosing, schedule, supply number, refill number and frequency, and the appropriateness of a variety of drug utilization management controls.

2) The Vendor shall make recommendations to the Agency for other medications, including new therapies.

x. Performance Measures for Treating Patients with Sickle Cell Disease

1) The Vendor shall produce a report containing a summary of existing performance measures with the goal of improving the health care for individuals with SCD.

2) The Vendor shall conduct an assessment to identify the performance measures that are most likely to effectively evaluate and track quality of care indicators including patient experience, prevention of disease complications and SCD health outcomes.

3) The Vendor shall provide a summary of any gaps the group feels new proposed performance measures are important, if applicable.

xi. External Funding Opportunities for a Florida Consortium of Centers of Excellence in Sickle Cell Disease

1) The Vendor shall identify and summarize at least 3 external funding opportunities. The summary shall include the following elements, at a minimum:

a) Name of the external funding organization/entity and website for applying;

DocuSign Envelope ID: DD7321A2-D5CB-4AD8-B034-D06BEE39C3E1DocuSign Envelope ID: 997AE366-BC46-4F1F-A3C1-D98CC8DA57D5

AHCA Contract No. MED216, Amendment No. 5, Page 5 of 7

b) Brief summary of the funding opportunity;

c) Due date of the application for the funding opportunity;

d) Qualifications to determine a potential lead/principal investigator;

e) Contact information for any individual(s) interested in serving as a lead/principal investigator; and,

f) Contact information for any individual(s) interested in applying for external funding – not to be restricted to SCD project workgroup members and/or SCD project researchers.

c. Project 3: Biennial Sickle Cell Disease Study Report

The purpose of this project is to conduct a study and produce a report on Medicaid recipients with sickle cell disease as described in Section 409.9125, Florida Statutes. Beginning November 1, 2024, and by November 1 every other year thereafter, the Agency shall submit a report of its findings and recommendations from the preceding 2-year review to the Governor, the President of the Senate, the Speaker of the House of Representatives, the Office of Minority Health and Health Equity, and the Rare Disease Advisory Council. The Agency shall also publish the report on its website in a manner that is easily accessible by the public.

The Vendor shall conduct the following activities, at a minimum, in meeting the requirements of this Contract:

i. Conduct a review to determine whether the available covered medications, treatments, and services for sickle cell disease are adequate to meet the needs of Medicaid recipients diagnosed with such disease and whether the Agency should seek to add additional medications, treatments, or services to improve outcomes.

ii. Population 1: Identify the total number of Medicaid recipients diagnosed with sickle cell disease.

iii. Population 2: Identify the number of recipients who experienced two or more emergency room visits or two or more hospital inpatient admissions in a 12-month period, including the length of stay and the total related expenditures, both medical and pharmaceutical, for those recipients.

iv. For both populations, provide the following detailed information:

1) Age and population demographics characteristics

DocuSign Envelope ID: DD7321A2-D5CB-4AD8-B034-D06BEE39C3E1DocuSign Envelope ID: 997AE366-BC46-4F1F-A3C1-D98CC8DA57D5 http://www.leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&Search_String=&URL=0400-0499/0409/Sections/0409.91235.html http://www.leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&Search_String=&URL=0400-0499/0409/Sections/0409.91235.html

AHCA Contract No. MED216, Amendment No. 5, Page 6 of 7

2) Health care utilization patterns

3) Total expenditures for both pharmaceutical and medical services provided by the Medicaid program contracted with managed care plans, per region, for the care of the Florida Medicaid recipients that are specifically designed or certified to provide health care coordination and health care access for individuals with SCD.

v. Conduct an assessment of the Agency’s existing payment methodologies for approved treatment or drug products for the treatment of sickle cell disease in the inpatient setting and assess whether such payment methodologies result in barriers to access to care.

vi. If barriers to access are identified, assess whether such methodologies may be modified or improved through the adoption of revised or new policies.

vii. Consult with a dedicated sickle cell disease medical treatment and research center which maintains a sickle cell patient database and tracks sickle cell disease outcome measures.

viii. Complete any additional analyses requirements as stipulated by the Florida Legislature and submit the findings accordingly.

3. Attachment I, Scope of Services, Exhibit A-1, Revised Deliverables, Financial

Consequences, and Performance Standards is hereby deleted in its entirety and replaced with Exhibit A-2, Revised Deliverables, Financial Consequences, and Performance Standards attached hereto and made a part of this Contract. All references in this Contract to Exhibit A-1 shall hereinafter also refer to Exhibit A-2.

All provisions not in conflict with this Amendment are still in effect and are to be performed at the level specified in this Contract.

This Amendment and all its attachments are hereby made a part of this Contract.

This Amendment cannot be executed unless all previous Amendments to this Contract have been fully executed.

REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

DocuSign Envelope ID: DD7321A2-D5CB-4AD8-B034-D06BEE39C3E1DocuSign Envelope ID: 997AE366-BC46-4F1F-A3C1-D98CC8DA57D5

AHCA Contract No. MED216, Amendment No. 5, Page 7 of 7

IN WITNESS WHEREOF, the Parties hereto have caused this seventeen (17) page Amendment to be executed by their officials thereunto duly authorized. This Amendment is not valid until signed and dated by both Parties.

FLORIDA MEDICAL SCHOOLS QUALITY

NETWORK, INC

STATE OF FLORIDA, AGENCY FOR

HEALTH CARE ADMINISTRATION

SIGNED

BY:

SIGNED

BY:

NAME: NAME:

TITLE: TITLE:

DATE: DATE:

List of Attachments included as part of this Amendment:

Specify Type Number Description Attachment I Exhibit A-2 Revised Deliverables, Financial

Consequences, and Performance Standards (10 pages)

REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

DocuSign Envelope ID: DD7321A2-D5CB-4AD8-B034-D06BEE39C3E1

EVP USF Health, Dean, Morsani College of Medicine

Dr. Charles Lockwood

6/26/2024 | 17:05 EDT

DocuSign Envelope ID: 997AE366-BC46-4F1F-A3C1-D98CC8DA57D5

6/30/2024

Chief of Staff

Stefan Grow

ATTACHMENT I

EXHIBIT A-2

REVISED DELIVERABLES, FINANCIAL CONSEQUENCES, AND PERFORMANCE

STANDARDS

AHCA Contract No. MED216, Exhibit A-2, Page 1 of 10

1.

DELIVERABLE 1

D01: Donor Milk Bank Timeline

SUPPORTING DOCUMENTATION

The Vendor shall submit a timeline that provides a description of the activities and due dates that shall be completed for the Study on the Use of Donor Human Milk as a supplement to newborn care for infants born prematurely and hospitalized within the NICU in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

July 30, 2021, or within five (5) days of execution of this Contract, whichever is sooner

(COMPLETED)

AMOUNT

N/A

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

2.

DELIVERABLE 2

D02: Donor Human Milk Banks

SUPPORTING DOCUMENTATION

The Vendor shall submit a list of donor human milk banks and companies supplying donor-derived human milk to infants in Florida in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

September 1, 2021 (COMPLETED)

AMOUNT

N/A

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

DocuSign Envelope ID: DD7321A2-D5CB-4AD8-B034-D06BEE39C3E1DocuSign Envelope ID: 997AE366-BC46-4F1F-A3C1-D98CC8DA57D5

AHCA Contract No. MED216, Exhibit A-2, Page 2 of 10

3.

DELIVERABLE 3

D03: Donor Human Milk Safety

SUPPORTING DOCUMENTATION

The Vendor shall submit an itemized list and description of the safety considerations in utilizing human milk for newborns in the NICU and the adulterants and contaminants that can be transmitted via human milk in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

September 17, 2021 (COMPLETED)

AMOUNT

$115,988.33

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 3 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to ten percent (10%) of the total invoiced amount.

4.

DELIVERABLE 4

D04: Donor Human Milk Data

SUPPORTING DOCUMENTATION

The Vendor shall submit data showing the use by Florida hospitals of donor human milk made available via donor human milk banks and the related health outcomes and achieved cost-savings for both Medicaid and commercial payors regarding newborn care within a NICU in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

September 24, 2021 (COMPLETED)

AMOUNT

$115,988.33

DocuSign Envelope ID: DD7321A2-D5CB-4AD8-B034-D06BEE39C3E1DocuSign Envelope ID: 997AE366-BC46-4F1F-A3C1-D98CC8DA57D5

AHCA Contract No. MED216, Exhibit A-2, Page 3 of 10

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 4 in the time and manner specified in

5.

DELIVERABLE 5

D05: Donor Human Milk Data Recommendations

SUPPORTING DOCUMENTATION

The Vendor shall submit recommendations of best practices which must address, at a minimum: the operation of a donor human milk tissue bank that facilitates the donation, processing and distribution of donor human milk tissue and donor human milk tissue derivatives; procedures for donation and distribution of donor human milk tissue and donor human milk tissue derivatives; and testing of donor human milk tissue and donor human milk tissue derivatives before donation, processing, and distribution to ensure the absence of adulterants and other contaminants, in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.a.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

September 24, 2021 (COMPLETED)

AMOUNT

$115,988.34

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 5 in the time and manner specified in

6.

DELIVERABLE 6

Draft Sickle Cell Disease Study Report

SUPPORTING DOCUMENTATION

The Vendor shall submit a draft sickle cell disease study report in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B. Services Provided by the Vendor, Item 1.b.

DocuSign Envelope ID: DD7321A2-D5CB-4AD8-B034-D06BEE39C3E1DocuSign Envelope ID: 997AE366-BC46-4F1F-A3C1-D98CC8DA57D5

AHCA Contract No. MED216, Exhibit A-2, Page 4 of 10

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

November 1, 2022, or as otherwise approved by the Agency. (COMPLETED)

AMOUNT

$118,222.20

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.b.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 1 in the time and manner specified in

7.

DELIVERABLE 7

Final Draft Sickle Cell Disease Study Report

SUPPORTING DOCUMENTATION

The Vendor shall submit a draft sickle cell disease study report in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B. Services Provided by the Vendor, Item 1.b.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

December 1, 2022, or as otherwise approved by the Agency. (COMPLETED)

AMOUNT

$78,814.80

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.b.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 2 in the time and manner specified in

8.

DELIVERABLE 8

Criteria for Florida Centers of Excellence for Sickle Cell Disease

SUPPORTING DOCUMENTATION

The Vendor will submit a summary in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.b.

DocuSign Envelope ID: DD7321A2-D5CB-4AD8-B034-D06BEE39C3E1DocuSign Envelope ID: 997AE366-BC46-4F1F-A3C1-D98CC8DA57D5

AHCA Contract No. MED216, Exhibit A-2, Page 5 of 10

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

2/10/2023 (COMPLETED)

AMOUNT

$9,755.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.b.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 8 in the time and manner specified in

9.

DELIVERABLE 9

Provider Education on Treating Patients with Sickle Cell Disease

SUPPORTING DOCUMENTATION

The Vendor will submit a summary in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.b.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

4/28/2023 (COMPLETED)

AMOUNT

$10,000.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.b.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 9 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent of the total invoiced amount.

10. DELIVERABLE 10

Preferred Drug List for Treating Patients with Sickle Cell Disease

DocuSign Envelope ID: DD7321A2-D5CB-4AD8-B034-D06BEE39C3E1DocuSign Envelope ID: 997AE366-BC46-4F1F-A3C1-D98CC8DA57D5

AHCA Contract No. MED216, Exhibit A-2, Page 6 of 10

11.

DELIVERABLE 11

Performance Measures for Treating Patients with Sickle Cell Disease

SUPPORTING DOCUMENTATION

The Vendor will submit a summary in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.b.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

4/21/2023 (COMPLETED)

AMOUNT

$8,000.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.b.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 11 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent of the total invoiced amount.

SUPPORTING DOCUMENTATION

The Vendor will submit a summary in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.b.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

3/31/2023 (COMPLETED)

AMOUNT

$20,000.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1..

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 10 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent of the

DocuSign Envelope ID: DD7321A2-D5CB-4AD8-B034-D06BEE39C3E1DocuSign Envelope ID: 997AE366-BC46-4F1F-A3C1-D98CC8DA57D5

AHCA Contract No. MED216, Exhibit A-2, Page 7 of 10

13.

DELIVERABLE 13

Biennial Sickle Cell Disease (SCD) Report Outline (Calendar Years 2022 and 2023)

SUPPORTING DOCUMENTATION

The Vendor shall develop and submit a Sickle Cell Disease Report outline for the biennial report due beginning November 1, 2024.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

February 1, 2024

AMOUNT

$20,000.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.c.

FINANCIAL CONSEQUENCES

Failure to complete and submit the deliverables that meet the minimum quality standards in the time and manner specified in accordance with this Contract will result in a payment reduction equal to ten percent (10%) of the total invoiced amount.

12.

DELIVERABLE 12

External Funding Opportunities for a Florida Consortium of Centers of Excellence in Sickle Cell Disease

SUPPORTING DOCUMENTATION

The Vendor will submit a summary in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.b.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

5/19/2023 (COMPLETED)

AMOUNT

$5,208.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.b.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 12 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent of the

DocuSign Envelope ID: DD7321A2-D5CB-4AD8-B034-D06BEE39C3E1DocuSign Envelope ID: 997AE366-BC46-4F1F-A3C1-D98CC8DA57D5

AHCA Contract No. MED216, Exhibit A-2, Page 8 of 10

14.

DELIVERABLE 14

Draft Sickle Cell Disease (SCD) Study Report (Calendar Year 2022)

SUPPORTING DOCUMENTATION

The Vendor shall develop and submit a Sickle Cell Disease Draft Report in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B. Services Provided by the Vendor, Item 1.c, and shall include, at a minimum, the following components: the purpose of the report; an executive summary;

consultations; background fundamentals of sickle cell disease; findings, including the total number of Medicaid recipients diagnosed with Sickle Cell Disease, age and population demographics of people with SCD, health care utilization patterns of Florida Medicaid recipients with SCD, expenditures for Florida Medicaid recipients with SCD, high-utilizers of healthcare services, and clinical treatment programs; and appendix including, methods, pharmaceutical utilization and expenditures, expenditures for medical services in high-utilizers and low utilizers with SCD, and expenditures of pharmaceutical services in low versus high utilizer populations.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

May 30, 2024

AMOUNT

$200,000.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1. c.

FINANCIAL CONSEQUENCES

Failure to complete and submit the deliverables that meet the minimum quality standards in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent of the total invoiced amount.

DocuSign Envelope ID: DD7321A2-D5CB-4AD8-B034-D06BEE39C3E1DocuSign Envelope ID: 997AE366-BC46-4F1F-A3C1-D98CC8DA57D5

AHCA Contract No. MED216, Exhibit A-2, Page 9 of 10

15.

DELIVERABLE 15

Final Draft Sickle Cell Disease (SCD) Study Report (Calendar Year 2022)

SUPPORTING DOCUMENTATION

The Vendor shall develop and submit a Sickle Cell Disease Final Report in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B. Services Provided by the Vendor, Item 1.c, and shall include, at a minimum, the following components: the purpose of the report, an executive summary;

consultations; background fundamentals of sickle cell disease; findings, including the total number of Medicaid recipients diagnosed with Sickle Cell Disease, age and population demographics of people with SCD, health care utilization patterns of Florida Medicaid recipients with SCD, expenditures for Florida Medicaid recipients with SCD, high-utilizers of healthcare services, and clinical treatment programs; and appendix including, methods, pharmaceutical utilization and expenditures, expenditures for medical services in high-utilizers and low utilizers with SCD, and expenditures of pharmaceutical services in low versus high utilizer populations.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

June 30, 2024

AMOUNT

$30,000.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.c.

FINANCIAL CONSEQUENCES

Failure to complete and submit the deliverables that meet the minimum quality standards in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent of the total invoiced amount.

DocuSign Envelope ID: DD7321A2-D5CB-4AD8-B034-D06BEE39C3E1DocuSign Envelope ID: 997AE366-BC46-4F1F-A3C1-D98CC8DA57D5

AHCA Contract No. MED216, Exhibit A-2, Page 10 of 10

REMAINDER OF PAGES INTENTIONALLY LEFT BLANK

16.

DELIVERABLE 16

Final Sickle Cell Disease (SCD) Study Report (Calendar Years 2022 and 2023)

SUPPORTING DOCUMENTATION

The Vendor shall develop and submit a revised Sickle Cell Disease Final Report in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.c, and shall include, at minimum, the data analysis for calendar years (CYs) 2022 and 2023 and all of the Agency’s feedback and requested edits.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

October 31, 2024

AMOUNT

N/A

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.c.

DocuSign Envelope ID: DD7321A2-D5CB-4AD8-B034-D06BEE39C3E1DocuSign Envelope ID: 997AE366-BC46-4F1F-A3C1-D98CC8DA57D5